Additionally, trials combining RT with a dual checkpoint blockade (e.g., anti-CTLA4 and anti-PD-1/PD-L1) have shown promise in overcoming resistance by modulating the tumor microenvironment and reversing T-cell exhaustion [269]. Here, CTLA4 is linked to neoplasm.